Description
A CB2 agonist (Ki = 40.3 nM) selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively); reduces differences in hind paw weight bearing between MIA- and saline-injected knees in a rat model of knee joint-related chronic pain induced by MIA at ≥0.1 mg/kg; dose-dependently reduces paclitaxel-induced mechanical and cold allodynia in mice and prevents development of morphine tolerance at 3 mg/kg per day for 12 days; reduces paclitaxel-induced allodynia in morphine-tolerant mice
Formal name: 8-(2-chlorophenyl)-2-methyl-6-(4-methyl-1-piperazinyl)-9-(tetrahydro-2H-pyran-4-yl)-9H-purine
Synonyms:
Molecular weight: 426.9
CAS: 1231220-79-3
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Neuroscience|Pain Research